Skip to main content
All lobbying filings

KELLEY DRYE & WARREN LLP

Lobbying for LABORATORY CORPORATION OF AMERICA HOLDINGS · Clinical laboratory

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2026 · North Carolina · House · Senate · $110,000.00 income · posted Jul 20, 2026

Official filing document

 Bills named in this filing 6
 Lobbying activity 1
Health Issues

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, and H.R. 9393, the Lower Costs, More Transparency Act, provisions relating to lab test price transparency; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem